CCL22 signaling contributes to sorafenib resistance in hepatitis B virus-associated hepatocellular carcinoma

Yanan Gao,Xing Fan,Nan Li,Chengzhi Du,Bin Yang,Wenhao Qin,Jing Fu,Geoffrey J. Markowitz,Hongyang Wang,Jianli Ma,Shuqun Cheng,Pengyuan Yang

Pharmacological Research（2020）

引用 19|浏览96

暂无评分

摘要

•Lymphocytes-mediated immunity was involved in sorafenib resistance.•Sorafenib upregulated CCL22 and CCL17 via TNF-α-RIP1-NF-κB signaling pathway.•Combination therapy enhanced the antitumor efficacy to overcome drug resistance.•Blocking CCL22 signaling could be a potential therapeutic strategy for HBV-associated HCC.

查看译文

关键词

HCC,HBV,Sora,CCR4,TNF

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要